10.90
price down icon5.71%   -0.66
 
loading
전일 마감가:
$11.56
열려 있는:
$11.61
하루 거래량:
2.83M
Relative Volume:
1.31
시가총액:
$1.33B
수익:
$631.73M
순이익/손실:
$-239.78M
주가수익비율:
-5.396
EPS:
-2.02
순현금흐름:
$-33.45M
1주 성능:
-11.49%
1개월 성능:
-32.55%
6개월 성능:
-52.63%
1년 성능:
-76.61%
1일 변동 폭
Value
$10.83
$11.85
1주일 범위
Value
$10.83
$13.12
52주 변동 폭
Value
$10.80
$48.42

10X 제노믹스 Stock (TXG) Company Profile

Name
명칭
10 X Genomics Inc
Name
전화
(925) 401-7300
Name
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Name
직원
1,306
Name
트위터
@10xgenomics
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
TXG's Discussions on Twitter

TXG을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Health Information Services icon
TXG
10 X Genomics Inc
10.90 1.33B 631.73M -239.78M -33.45M -2.02
Health Information Services icon
VEEV
Veeva Systems Inc
225.79 36.66B 2.66B 665.91M 1.08B 4.05
Health Information Services icon
DOCS
Doximity Inc
72.37 13.58B 516.85M 174.11M 217.38M 0.87
Health Information Services icon
SOLV
Solventum Corp
73.02 12.61B 8.26B 66.00M 1.17B 0.3682
Health Information Services icon
TEM
Tempus Ai Inc
68.09 10.72B 640.44M -743.28M -206.93M -11.29
Health Information Services icon
HQY
Healthequity Inc
108.60 9.41B 1.15B 96.70M -161.99M 1.09

10X 제노믹스 Stock (TXG) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-13 다운그레이드 Leerink Partners Outperform → Market Perform
2024-09-03 개시 Leerink Partners Outperform
2024-07-22 업그레이드 Jefferies Hold → Buy
2024-07-18 다운그레이드 JP Morgan Overweight → Neutral
2024-07-10 다운그레이드 Deutsche Bank Buy → Hold
2024-06-27 다운그레이드 Wolfe Research Outperform → Peer Perform
2024-06-25 다운그레이드 Guggenheim Buy → Neutral
2024-06-03 재개 Jefferies Hold
2024-05-01 다운그레이드 TD Cowen Buy → Hold
2023-12-14 개시 Guggenheim Buy
2023-12-13 개시 Wolfe Research Outperform
2023-12-12 업그레이드 BofA Securities Underperform → Neutral
2023-07-05 재개 JP Morgan Overweight
2023-05-10 개시 Barclays Overweight
2023-03-31 개시 Stephens Overweight
2023-02-02 개시 UBS Neutral
2022-12-14 개시 Deutsche Bank Buy
2022-08-18 다운그레이드 Goldman Neutral → Sell
2022-07-25 개시 Canaccord Genuity Buy
2022-07-15 다운그레이드 BofA Securities Neutral → Underperform
2022-07-15 다운그레이드 William Blair Outperform → Mkt Perform
2021-10-15 재개 Cowen Outperform
2021-09-14 다운그레이드 BofA Securities Buy → Neutral
2021-03-15 개시 William Blair Outperform
2020-12-02 개시 Goldman Neutral
2020-09-09 개시 Morgan Stanley Overweight
2020-07-10 개시 Stifel Buy
2020-03-05 개시 Guggenheim Buy
2020-01-07 개시 Citigroup Buy
2019-10-07 개시 BofA/Merrill Buy
2019-10-07 개시 Cowen Outperform
2019-10-07 개시 JP Morgan Overweight
2019-09-24 개시 Evercore ISI Outperform
모두보기

10X 제노믹스 주식(TXG)의 최신 뉴스

pulisher
Feb 21, 2025

10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St

Feb 21, 2025
pulisher
Feb 21, 2025

Alberta Investment Management Corp Makes New $3.21 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 21, 2025
pulisher
Feb 19, 2025

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - Eastern Progress

Feb 19, 2025
pulisher
Feb 19, 2025

William Blair Estimates 10x Genomics Q3 Earnings - MarketBeat

Feb 19, 2025
pulisher
Feb 18, 2025

10x Genomics (NASDAQ:TXG) Lowered to "Hold" Rating by Leerink Partnrs - MarketBeat

Feb 18, 2025
pulisher
Feb 18, 2025

10x Genomics (NASDAQ:TXG) Shares Up 8.3%Still a Buy? - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Citigroup Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

10x Genomics (NASDAQ:TXG) Price Target Cut to $12.00 by Analysts at JPMorgan Chase & Co. - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

10x Genomics' SWOT analysis: genomics firm faces NIH funding headwinds - Investing.com

Feb 17, 2025
pulisher
Feb 17, 2025

10x Genomics (NASDAQ:TXG) Shares Gap Down on Disappointing Earnings - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Leerink Partners Downgrades 10x Genomics (NASDAQ:TXG) to Market Perform - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

10x Genomics (NASDAQ:TXG) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat

Feb 16, 2025
pulisher
Feb 16, 2025

Entropy Technologies LP Purchases 27,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 16, 2025
pulisher
Feb 15, 2025

10x Genomics (NASDAQ:TXG) Price Target Cut to $26.00 by Analysts at Morgan Stanley - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Leerink Partnrs Forecasts 10x Genomics Q1 Earnings - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Barclays Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

Canaccord Genuity Group Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

UBS Group Cuts 10x Genomics (NASDAQ:TXG) Price Target to $14.00 - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

10x Genomics falls on quarterly EPS miss, 2025 revenue guidance concern - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Morgan Stanley Trims Price Target on 10x Genomics to $26 From $28, Keeps Overweight Rating - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

10x Genomics Inc Reports Q4 Revenue of $165M, Beating Estimates; EPS of -$0.40 Misses Expectations - GuruFocus.com

Feb 14, 2025
pulisher
Feb 14, 2025

Sumitomo Mitsui Trust Group Inc. Has $82.05 Million Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

10X Genomics Earnings Call: Innovations Amidst Revenue Challenges - TipRanks

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 - Victoria Advocate

Feb 13, 2025
pulisher
Feb 13, 2025

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties - Benzinga

Feb 13, 2025
pulisher
Feb 13, 2025

10X Genomics stock plunges to 52-week low of $11.89 - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics, Inc. Provides Earnings Guidance for the Year 2025 -February 12, 2025 at 04:05 pm EST - Marketscreener.com

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

UBS Adjusts Price Target on 10x Genomics to $14 From $20, Keeps Neutral Rating -February 13, 2025 at 10:09 am EST - Marketscreener.com

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics (NASDAQ:TXG) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics Shares Tumble on Fear Over Cuts to NIH - Barron's

Feb 13, 2025
pulisher
Feb 13, 2025

Leerink Partners Downgrades 10x Genomics to Market Perform From Outperform, Adjusts Price Target to $12 From $25 - Marketscreener.com

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics, Inc. SEC 10-K Report - TradingView

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics revenue increases 10% to USD 165M in Q4 2024 - Medical Buyer

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigat - GuruFocus.com

Feb 13, 2025
pulisher
Feb 13, 2025

10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance

Feb 13, 2025
pulisher
Feb 12, 2025

10x Genomics: Q4 Earnings Snapshot - CT Insider

Feb 12, 2025
pulisher
Feb 12, 2025

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025 - BioSpace

Feb 12, 2025
pulisher
Feb 12, 2025

Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings - Yahoo Finance

Feb 12, 2025
pulisher
Feb 12, 2025

Earnings call transcript: 10X Genomics Q4 2024 misses EPS forecast, stock dips - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Feb 12, 2025
pulisher
Feb 12, 2025

10x Genomics: Q4 Earnings Snapshot -February 12, 2025 at 04:54 pm EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations - Yahoo Finance

Feb 12, 2025
pulisher
Feb 12, 2025

Earnings Flash (TXG) 10x Genomics Reports Q4 Revenue $165M, vs. FactSet Est of $159.8M - Marketscreener.com

Feb 12, 2025

10X 제노믹스 (TXG) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

10X 제노믹스 주식 (TXG) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Saxonov Serge
Chief Executive Officer
Nov 22 '24
Sale
13.69
6,693
91,612
872,574
Hindson Benjamin J.
See Remarks
Nov 22 '24
Sale
13.69
5,807
79,485
339,897
$11.51
price down icon 9.30%
$13.17
price down icon 2.80%
$24.52
price down icon 0.49%
$19.49
price down icon 4.46%
health_information_services WAY
$42.21
price up icon 2.95%
health_information_services HQY
$108.60
price down icon 2.79%
자본화:     |  볼륨(24시간):